These results show not only that LAIR-1 is a viable target for therapeutic intervention of AML, but that the NC525 agonist antibody can work in concert with current clinical therapeutics to eradicate disease and improve patient outcomes. Here, LAIR1 is linked to acute myeloid leukemia.